Dr. Kevin Kelly, Testicular Cancer: Diagnosis and
Treatment
April 20, 2008
Welcome to Yale Cancer Center answers with Dr. Ed Chu and Dr. Ken Miller. I am Bruce Barber. Dr. Chu is Deputy Director and Chief of Medical Oncology at Yale Cancer Center, and Dr. Miller is a Medical Oncologist specializing in pain and palliative care, and he also serves as the Director of the Connecticut Challenge Survivorship Clinic. If you would like to join the discussion, you can contact the doctors directly at canceranswers@yale.edu or 1-888-234-4YCC. This evening, Dr. Ed Chu welcomes Dr. Kevin Kelly. Dr. Kelly is the Co-Director of the Yale Cancer Center Prostate and Urologic Cancer Program and Associate Professor of Medical Oncology at the Yale Cancer Center.
Kelly
Testicular cancer is a group of cancers that evolve or arise from
the testicle itself. There are several types of testicular
cancers. There are typically germ cell tumors.
In germ cell tumors there are two main types called seminoma and
nonseminomatous germ cell tumors. But, there are other types
of testicular cancers that can arise in different areas of the
testicles that either are more like a sarcoma or they can even be
lymphomas or other types of tumors that arise, but the most common
type that we see is the germ cell tumors, which are either
seminomatous or nonseminomatous germ cell tumors.
Chu
How common is this disease?
Kelly
This is actually a very rare disease if you look at all
malignancies. There are around 8,000 cases diagnosed in the
United States per year. However, if you look at young male adults,
it is the most common cancer that is diagnosed. It is more
common than lymphomas and leukemia's combined. In patients from the
age of around 15 to mid-20s, it is the most common tumor
diagnosed.
Chu
What are the usual presenting symptoms that a male needs to be
aware of?
Kelly
The major concern is increasing mass in the testicle itself.
It could be painful or it may be asymptomatic. Some people do
get breast tenderness, which is the first sign. Other patients
present with back pain, which is a sign that the cancer may have
spread. It is very important for young males, just like we
teach with breast cancer, to do breast exams. Testicular exams are
a very important component that should be taught to young males as
they are growing up. A lot of this is being taught in the pediatric
offices now, about the appropriate screening for testicular
cancer.
Chu
Interesting. What age should boys start self-testicular
exams?
Kelly
Once they start puberty is when they should actually start. Any
abnormality in the testicle should be brought to the attention of
their physician. Again, that is the best way to help detect
testicular cancer early.
3:28into mp3 file
http://www.yalecancercenter.org/podcast/Answers_Apr-20-08.mp3
Chu
What are the main risk factors for developing testicular
cancer?
Kelly
There is a familial trait to germ cell tumors, a family
history. Other risk factors are if you had an undescended
testicle at birth and it was brought down, or you still have an
undescended testicle. Syndromes such as Klinefelter syndrome have a
higher incidence of testicular cancer.
Chu
But for the majority of folks?
Kelly
It's sporadic.
Chu
Take us through the process Kevin, there is a mass in the testis,
and you then go to your general internist or family doctor to have
it evaluated?
Kelly
Typically it is found by an internist or general practitioner who
notices this abnormality, then it is seen by the urologist who can
evaluate it because not all masses within the testicles are
cancer. There are what we call benign masses and you really
need an expert who sees this all the time to evaluate it, typically
a urologist. If there is a suspicious mass, the first step is
an ultrasound of the testicles. If there is something
suspicious on the ultrasound, what we typically do is remove the
testicle. We remove it through an incision in the groin and then
the pathologist does examine the specimen at that point.
Chu
There is no indication for a biopsy first before removing the
entire testis?
Kelly
No. The problem is that if there is a tumor in the testis,
and you biopsy, you can track tumor through and infect the scrotal
skin. If that happens then it is a more serious spread of the
cancer. The most common way that we diagnose if there is a
suspicious mass within the testicle is with what we call inguinal
orchiectomy.
Chu
What happens after the surgery is performed?
Kelly
Typically before or after surgery we draw blood because germ cell
tumors typically have tumor markers within the blood that are very
diagnostic for certain types of tumors. There are three types
that we look at. They are called alphafetoprotein, beta HCG
and LDH. These three markers are very important to how we
diagnose and manage germ cell tumors.
Chu
Are those three markers elevated in all types of testicular
cancer?
Kelly
No they are not. Depending on what type, if you have
seminoma versus nonseminomatous tumor, they would be differently
elevated. But in the majority, one of those three is elevated
in more advanced stages of germ cell tumor.
6:52into mp3 file http://www.yalecancercenter.org/podcast/Answers_Apr-20-08.mp3
Chu
Would one do any type of imaging study like CAT scan to see if the
cancer is spread throughout the body?
Kelly
That is correct. The most common places where germ cell
tumors spread to are the back, the abdomen, or what we call the
retroperitoneum. A CT scan can visualize that very carefully.
However, germ cell is very specialized because we know where
exactly it goes into the body. Even a small lymph node may
harbor cancer and physicians have to be very suspicious because
germ cell can spread very quickly and very easily. An
important point is that we know delay in diagnosis of the germ cell
tumors actually has a dramatic impact on the overall outcome of the
germ cell tumors. When a patient does have a testicular mass,
it needs to be worked up efficiently and expeditiously because
delay in diagnosis decreases the ability to cure that patient.
Chu
Presumably if there is a delay in the diagnosis the cancer has a
chance to spread.
Kelly
Particularly the nonseminomatous germ cell tumors are rapidly
growing tumors, and they can actually spread. Once we have
diagnosed that, we work these patients up very quickly to ensure
that they get the appropriate treatment to maximize the cure.
Chu
At the Yale Cancer Center, you oversee the genitourinary urologic
cancers as a multi-disciplinary team. Can you tell our
listeners out there who is involved in that team and why that team
is so important?
Kelly
It is critical that there is a team of us that take care of these
patients. It really exemplifies how a team approach can not only
diagnose and treat but actually cure patients. It takes all three
of us on the team to do it. It is composed of a medical oncologist,
a urologic surgeon, and the radiation oncologist. Each have a
role in the treatment of germ cell tumor and we will talk a little
bit further about that, but the real role of each is to cure a
patient with germ cell tumor. It will take a combination of all our
specialties in order to have an optimum outcome for these
patients.
Chu
Once you evaluate a patient with this multi-disciplinary approach
and a diagnosis is made, the patient undergoes surgical resection
and then you try to figure out what stage the disease is. Can
you go through the different stages of testicular cancer?
Kelly
Typically we are talking of germ cell tumors not testicular
cancers because germ cells are the most common tumors, and they are
divided into two types. One is seminoma and one is
nonseminomatous germ cell tumor. Once they have a surgical
resection, typically we do a CAT scan of the chest, abdomen and
pelvis to look at the extent of disease. We will repeat the
tumor markers, which are the
10:29into mp3 file http://www.yalecancercenter.org/podcast/Answers_Apr-20-08.mp3
beta HCG, alphafetoprotein and LDH after surgery, because if it is elevated beforehand and it comes down, it gives us more information. We watch those serially because we know that there is a certain half-life of these markers, and they should come down appropriately after resection of tumor or treatment. At that point, depending if you have a seminoma, or very localized disease, radiation therapy after the orchiectomy may be appropriate. For a patient who has a nonseminomatous germ cell tumor, depending on the pathology results, either chemotherapy or surgical resection of any residual or small lymph nodes in the back of the abdomen may be an appropriate first step.
Chu
We would like to remind you to email your questions to canceranswers@yale.edu or
call 1-888-234-4YCC. At this time, we are going to take a
short break for medical minute. Please stay tuned to learn
more information about testicular cancer with our special guest,
Dr. Kevin Kelly.
Chu
Welcome back to Yale Cancer Center Answers. This is Dr. Ed
Chu, and I am here in the studio this evening with my special
guest, Dr. Kevin Kelly talking about the latest treatment options
and developments for testicular cancer. Kevin, before the
break we were talking about the different stages of testicular
cancer. For those just joining us after the break, can you
review what the different stages of testicular cancer are, just in
general?
Kelly
In a broad sense you can actually divide the patients into stage
I, II, and III. Stage I is more or less localized to the
testicle. Stage II is if you have an involvement of the lymph
nodes in the abdomen, and stage III is more advanced disease. What
is interesting is that we an actually diagnose patients based on
the risk categories, and we look at patients not only for the
extent of disease based on stage, but their risk assessment. We can
do that by looking at where the cancer is, what type of cancer it
is, what the tumor markers are and whether HCG, alphafetoprotein,
or LDH are elevated. We can divide them into what we call
good risk, intermediate
13:54into mp3 file http://www.yalecancercenter.org/podcast/Answers_Apr-20-08.mp3
risk, and poor risk, and that helps our treatment. We know in seminomatous tumors that virtually all those tumors are only good risk and intermediate risk tumors. However, in the nonseminomatous germ cell tumors, you can have good risk, intermediate risk and poor risk tumors, and that really helps us designate what type of therapy these patients need.
Chu
Do those different risk categories also give an idea as to how
they would respond to treatment?
Kelly
Absolutely, that is why they were designed. Germ cell tumor
is the one tumor that we can actually cure, and that is an
important point. Over 90% of patients, we can cure with the
appropriate therapies; that includes surgery, radiotherapy, and
chemotherapy. Depending on your risk category, we will modify
the chemotherapy for the patients.
Chu
Probably the most dramatic example of such effective treatment
options for testicular cancer is the case of Lance Armstrong.
Kelly
Absolutely. He is the poster child for germ cell tumors, but
there are a lot of others out there with similar cases that also
have been cured from the tumor. When Lance Armstrong was
diagnosed he had very extensive disease, he even had disease to the
brain, and through extensive therapy for over a year, and with
resection of residual disease, he is cured from his cancer.
One of the points I do want to make is that what we do cures a
majority of germ cell tumors, but there is always a chance that
tumor can come back. You get the treatment but it is a
lifelong follow-up of these patients because these are young
patients and they can have secondary complications to the therapy
down the line.
Chu
We can get back to that. When I was down in Bethesda,
Maryland at the National Cancer Institute, we saw a number of young
military males presenting with testicular cancer. I can remember
the first question they would always ask was if they would become
sterile once we started chemotherapy. What are your thoughts
on that subject?
Kelly
We are always concerned about the fertility of these young men,
because most of them are not married, or newly married, and still
are looking forward to having a family. Typically before we
do either an orchiectomy or any therapy, we ask them to go to a
sperm bank first. The majority of these patients, even with the
diagnosis, have what we call low sperm counts, but after
chemotherapy, their sperm count, or the ability to be fertile
afterwards, markedly decreases. It is not zero, but it is
markedly low. We encourage all of our patients to use a sperm
bank before they start treatment, and that is a very easy
process.
17:21into mp3 file http://www.yalecancercenter.org/podcast/Answers_Apr-20-08.mp3
Chu
Can you give an approximation as to how many males might become
infertile because of the chemotherapy?
Kelly
What we always tell patients is that it is 100% will. We cannot
count on it even if they do have sperm, we cannot tell them if they
are going to be active, or if the number of sperm is going to be
adequate to have their spouse become pregnant. That is why
upfront we always encourage the sperm bank.
Chu
What has always impressed me about testicular cancer is how
sensitive it is to chemotherapy and radiation therapy. It is
very different than other diseases that you also take care of such
as prostate cancer and bladder cancer.
Kelly
Yes.
Chu
Is there any reason why this kind of cancer is so sensitive to
chemotherapy and radiation therapy?
Kelly
I thought you were going to tell me the answer Ed. That is a
question that has been asked a lot, and unfortunately, I do not
think we have a good explanation for it. Historically, germ
cell tumors were always incurable tumors. If you look back in
history, in the 1970s, this was a very fatal disease. It was
not until the mid 1970s, when multi-agent chemotherapy came in, and
there was a major effect when cisplatin-based chemotherapy was
invented. It dramatically changed how we treat germ cell
tumors. The impressive thing is what was done with germ cell
tumors. You had a lot of smart people in the field that did very
logical studies to optimize the treatment for germ cell tumors. It
really showed that working together with our surgical colleagues,
the urologist, the medical oncologist and the radiation oncologist,
to develop the most optimal program for these patients, pays off.
These trials are difficult to do because they are rare tumors;
however, our colleagues in Europe and the United States worked
together to do these large trials that showed us what the optimal
treatments for germ cell tumors are.
Chu
A significant advance came once cisplatinum was developed.
Kelly
Exactly. That was a huge breakthrough at that time and it had a
significant impact on germ cell tumors.
Chu
What are some of the short-term, immediate consequences and side
effects of the chemotherapy that you give patients with testicular
cancer?
Kelly
We give very aggressive chemotherapy to these patients and the
typical drugs that we give are either what we call toposide,
cisplatinum or a third drug called bleomycin. Depending on what
your risk category is at presentation, you may get two of those
drugs or three of those drugs. The major side effects that we
see
20:55into mp3 file http://www.yalecancercenter.org/podcast/Answers_Apr-20-08.mp3
with chemotherapy are that they can lower your blood counts. Blood counts are 3 components, your white cells, red cells and platelets, and chemotherapy can affect all three. Young men typically tolerate very high doses of chemotherapy very well and bounce back, but there are medications that can help them with white counts and red counts to get through the therapy. Other side effects that they may have are nausea and vomiting. We give very high doses of cisplatinum and that is one of the major difficulties. However, with the newer medications we have we can prevent nausea and over 90% of the patients seen are very aggressive with that. As we see these patients come through they actually have a very good quality of life and most of them continue to work while they receive chemotherapy. They do have other side effects such as hair loss; however, it all comes back within 4 to 6 weeks after the chemotherapy stops. Other things that can happen are that it can actually give you numbness and tingling in the hands and feet, but overtime it is reversible.
Chu
As far as we know, are there any long-term consequences of
chemotherapy treatment?
Kelly
Yes, and as we are following these patients out 10 years, 15 years
and 20 years, there are incidents where we particularly look at the
incidence of leukemia, because a lot of these drugs can cause
leukemia, but this occurs in around 2% of patients. That is
one of the reasons why we have long-term follow-up of these
patients. Another long-term side effect is cardiovascular
risk. The cardiovascular risk increases as time goes
out. We know that if you look at age control population, you
see that the incidence of cardiovascular disease is higher at a
younger age in these patients; so we need to watch them very
carefully. Two other things that do happen is that you can
get lung toxicities and this is particularly from one drug we give
called bleomycin. We just have to monitor that. The other is
a disease called Raynaud disease, which is very common with both
cisplatinum and bleomycin. This happens at a younger age than the
natural history of Raynaud disease.
Chu
What about if a patient is say, out 5 to 10 years from their
treatment and they were cured, do you still have to worry about the
risk of recurrence?
Kelly
Absolutely. We still watch these patients out to around 5
years. We still see them on a yearly basis. We want to
check their blood counts because that is one of the earliest signs
we see in people with leukemia. We may want to still do a
chest x-ray to make sure there is no recurrence. We will
check their tumor markers and they should continue follow-up for at
least 10 years, and subsequently even longer for any side effects
from the chemotherapy.
Chu
Who would typically then follow after say five years? Would
it be the medical oncologist, the urologist or both working
together?
24:24 into mp3 file http://www.yalecancercenter.org/podcast/Answers_Apr-20-08.mp3
Kelly
We typically work together, whether it is more convenient for the
urologist or medical oncologist. Typically, in those patients
who received chemotherapy or had more advanced disease, I have a
tendency to follow them because I am looking for more of the side
effects of chemotherapy. We are more tuned to that versus
somebody who has a very local disease which is typically followed
by the urologist.
Chu
Now suppose, God forbid, the testicular cancer comes back; the
patient has been diagnosed with recurrent disease. Are there
treatment options available at that point?
Kelly
Yes, there are, and the important thing is that this is still
curable at that point too. There are what we call salvage
chemotherapies which include a high-dose of chemotherapy. At times
we even do what we call transplants or stem cell transplants in
these patients. Even those who have the worst recurrence of
disease, there is still a portion of those patients that we can
cure.
Chu
If someone were out 8 to 10 years and presenting with new disease,
would you go right away to the high-dose therapy or could you go
back to the original therapy that they had received and had such
good results with?
Kelly
The question we would have here is, is this truly a recurrent
disease, or has this developed maybe in the opposite testicle? You
would have to differentiate that. One of things that we also
get concerned about with germ cell tumors is a rare phenomenon
called malignant transformation of a disease. Germ cell
tumors are very early cells of what we call primordial cells.
Primordial cells are certain cells that grow and can be what we
call teratoma, and those teratomas over time can transform into
other types of tumors, a sarcoma for instance, or they can even
become an adenocarcinoma. If we see a new mass, we always
like to re-biopsy to reestablish a diagnosis to optimize the
treatment for the patient.
Chu
In the setting of the teratoma that you just mentioned, would one
want to have surgical resection of that teratoma so they wouldn't
have to then worry about subsequent malignant transformation?
Kelly
Yes. Typically, after a patient gets chemotherapy upfront,
we reevaluate the patient and if there is any evidence of a mass,
whether in the lung, the back of the abdomen, or wherever, we take
that out because there are three possibilities that could be in
that residual mass; it could be a dead tumor, it could be a still
residual tumor or what we call teratoma. Teratoma is not
sensitive to chemotherapy and that is why we need to resect
it. If we do not resect it, then it has a chance to do what
we just discussed about malignant transformation.
27:33 into mp3 file http://www.yalecancercenter.org/podcast/Answers_Apr-20-08.mp3
Chu
Over the final couple minutes of the show, Kevin, can you just
tell our listeners what research is being done at the Yale Cancer
Center focusing on testicular cancer?
Kelly
One of the biggest quandaries that we're having in testicular
cancer is that the incidences are actually increasing over each
decade, and the epidemiology department here is looking at reasons
why. There is some concern that there may be an environmental
factor that is increasing the incidence of germ cell tumors.
This is a study being conducted by Dr. Zeng, here in our
epidemiology department, and also by other colleagues around the
world.
Chu
Kevin thanks so much for joining me this evening on the show.
It has been a terrific session and I look forward to having
you on a future show to discuss the further advances of testicular
cancer.
Kelly
It is a pleasure.
Chu
Until next week, this is Dr. Ed Chu from the Yale Cancer Center
wishing you a safe and healthy week.
If you have questions, comments, or would like to subscribe to our Podcast, go to www.yalecancercenter.or where you will also found transcripts of past broadcasts in written form. Next week, we will look at sexuality and cancer with Dr. Dr. Sharon Bober and Ellen Matloff.